Targeted Therapy for Cancer:
The Biomarker-to-Drug Matcher
The only cancer treatment category where the drug literally does not work without the matching mutation. Find which drug was built for your specific tumor alteration — and what to do when resistance develops.
Biomarker-to-Drug Matcher
Select your cancer type and the specific mutation found on your pathology or NGS report. The matcher shows only drugs with evidence of efficacy for that exact alteration — with US/EU and China approval status.
1. Select Cancer Type
2. Select Biomarker / Mutation
3. Select Treatment Line
2025-2026: The Inflection Year for Precision Oncology
Seven new FDA approvals across molecular targets for NSCLC alone arrived in 2025 — the full maturation of precision oncology. Here are the highlights that changed clinical practice.
Zongertinib (HER2-TKI)
Oral TKI selectively inhibiting HER2 while sparing wild-type EGFR. Achieved 75% ORR in platinum-pretreated NSCLC — a historically difficult subgroup. FDA Approved 2025
Telisotuzumab Vedotin (c-Met ADC)
c-Met-directed antibody-drug conjugate approved for non-squamous NSCLC with high c-Met overexpression. Expands ADC applicability beyond HER2 and Trop-2. FDA Approved 2025
Dato-DXd (TROP2 ADC) — Breast
TROP2-directed ADC improved PFS to 6.9 months vs 4.9 months for chemo in HR+/HER2- breast cancer. Part of the growing TROP2-targeted class across multiple solid tumors. FDA Approved 2025
The Drug Class Taxonomy: A Family Tree of Targeted Agents
Not an alphabet soup of drug names. Understand what kind of tool each drug is — and which category your matched drug belongs to.
💊 Tyrosine Kinase Inhibitors (TKIs)
Small-molecule pills that slip inside the cell and plug directly into the overactive signaling protein — blocking it from sending growth signals. Examples: Osimertinib (EGFR), Alectinib (ALK), Adagrasib (KRAS G12C), Imatinib (BCR-ABL).
Standard of Care🧬 Monoclonal Antibodies (mAbs)
Large proteins that bind to a target on the outside of the cancer cell, blocking the growth signal or flagging the cell for immune destruction. Examples: Trastuzumab (HER2), Cetuximab (EGFR), Bevacizumab (VEGF).
Standard of Care🚚 Antibody-Drug Conjugates (ADCs)
An antibody acts as a delivery truck, carrying a chemotherapy payload directly to the cancer cell and releasing it only inside the target. Examples: T-DXd / Enhertu (HER2), T-DM1 (HER2), Sacituzumab Govitecan (Trop-2), Telisotuzumab Vedotin (c-Met).
Standard of Care⚡ PROTACs & Molecular Glues (Emerging)
Instead of blocking a protein, these tag it for complete destruction by the cell's own cleanup system. Researchers are actively developing PROTACs to tackle KRAS G12D-mutated pancreatic cancers. Not yet standard of care — but the next frontier.
Clinical Trials / PreclinicalTumor-Agnostic Therapy: Biomarker First, Organ Second
This is a genuinely new concept that most patients don't have intuition for — and almost no patient-facing page foregrounds it.
Resistance: What Happens When the Drug Stops Working
Targeted therapy's defining clinical reality — and the topic almost no patient-facing page handles well.
What Is Acquired Resistance?
The tumor evolves a workaround. This can happen through a second mutation in the same target (e.g., EGFR T790M after first-generation EGFR inhibitors), amplification of a parallel pathway (e.g., MET amplification bypassing EGFR blockade), or histologic transformation (e.g., NSCLC transforming to small cell). The drug didn't "fail" — the cancer adapted, and a different drug is now needed.
What Happens Clinically Next?
Step 1: Repeat biopsy (tissue or liquid) to identify the new resistance mechanism. Step 2: If a resistance mutation is found, switch to a second-generation or third-generation drug targeting that new alteration (e.g., Osimertinib for EGFR T790M). Step 3: If no targetable resistance mechanism is identified, consider chemotherapy, clinical trial enrollment, or combination strategies.
Concrete Example: MET Amplification After EGFR Inhibition
MET amplification is a known resistance mechanism that emerges in patients with EGFR-mutated NSCLC after they progress on EGFR inhibitors. The cancer activates a completely different growth pathway to bypass the blocked EGFR signal. The solution: add a MET inhibitor (like Tepotinib or Capmatinib) to the existing EGFR TKI — or switch to a bispecific antibody targeting both EGFR and MET (like Amivantamab).
The Testing Gap: Millions of Patients Never Learn They Qualify
Uptake of biomarker testing remains suboptimal — studies show only about half of eligible patients receive the recommended genomic testing. This means a meaningful fraction of patients worldwide never even learn they qualify for a targeted drug.
Tissue Biopsy vs. Liquid Biopsy
Tissue NGS is the gold standard but can take 2-4 weeks and requires adequate tumor sample. Liquid biopsy (blood-based ctDNA testing) returns results faster — often within 7-10 days — and detects mutations shed by tumors throughout the body, including metastases a single tissue biopsy might miss. If tissue is insufficient or results are urgent, ask your oncologist about liquid biopsy as a complementary or alternative option.
What to Ask Your Oncologist
"Have I had a comprehensive NGS panel — not just a single-gene test?" A single-gene test for EGFR alone would miss ALK, ROS1, BRAF, MET, NTRK, RET, KRAS, and HER2 alterations. "Does my NGS panel cover fusions (ALK, ROS1, RET, NTRK, FGFR) — not just point mutations?" Fusion detection requires RNA-based sequencing, which not all NGS panels include. "If tissue NGS was insufficient or inconclusive, should we add a liquid biopsy?"
China vs. the West: An Honest Three-Layer Picture
Not a binary "cheaper/better" comparison. Three distinct trends define the 2025-2026 landscape.
Layer 1: China Is Rising — Fast
China has shifted from a fast-follower to a genuine source of first-in-class molecules in select areas. An analysis of 82 Chinese pharmaceutical companies found 259 multiregional clinical trials across 183 new molecular entities in oncology between 2015 and 2024. Zanubrutinib (BTK inhibitor) became the first small-molecule drug developed in China to receive both FDA and EMA approval.
Layer 2: The First-in-Class Gap Is Real but Closing
Between 2015 and 2021, 90 FDA-approved oncology drugs were granted, 32% of which were first-in-class, compared with 0% first-in-class originating from China in that period. China's drug development has largely followed a fast-follow strategy — me-too or me-better drugs building on international first-in-class experience. This is actively shifting, but the gap was real and recent.
Layer 3: Mechanism Overlap Is Substantial and Growing
Small molecules targeting EGFR, KDR, PARP, PDGFR, FLT1/4, FGFR, BTK, and BCR-ABL account for the majority of approvals in both the US and China. Many oncology therapeutics have recently become available in China less than four years after FDA approval. A PD-1/VEGF dual antibody from a Chinese firm is currently in a US trial with expected completion in late 2025 — if positive, it would mark a significant milestone in the bidirectional flow of drug approvals.
Leading Centers by Targeted Therapy Expertise
Each center is selected for specific, verifiable expertise — not a generic "top hospitals" list. Direct links to active clinical trials.
🇺🇸 EGFR & ALK Resistance — DFCI / MGH (Boston)
Dana-Farber and Mass General lead research on resistance mechanisms to EGFR and ALK inhibitors, including histologic transformation and off-target pathway activation. Active trials for 4th-generation EGFR TKIs.
View trials on ClinicalTrials.gov →🇨🇳 KRAS & Rare Fusions — Guangdong Lung Cancer Institute
China's leading center for KRAS G12C/G12D inhibitor trials and rare fusion-positive NSCLC (NRG1, FGFR). Fast-follower clinical development with domestic TKIs showing comparable efficacy to Western counterparts at lower cost.
View trials on ClinicalTrials.gov →🇪🇺 ADC Development — Gustave Roussy (Paris)
European reference center for Antibody-Drug Conjugate clinical development. Key site for T-DXd, T-DM1, and next-generation ADC trials across HER2, Trop-2, and c-Met targets in breast, gastric, and lung cancers.
View trials on ClinicalTrials.gov →🇨🇳 Tumor-Agnostic HER2 — Fudan University Shanghai Cancer Center
Leading site for tumor-agnostic HER2-directed therapy trials, including next-generation pan-HER ADCs (SHR-A1811) with superior pulmonary safety profiles compared to T-DXd. Active in breast, gastric, lung, and biliary HER2-altered cancers.
View trials on ClinicalTrials.gov →Frequently Asked Questions
No — and this is the single most important fact about targeted therapy. Unlike chemotherapy, which attacks all rapidly dividing cells, a targeted drug only works if the tumor carries the specific mutation the drug was designed to block. Taking a targeted drug without the matching mutation exposes you to side effects with zero expected benefit. Always insist on comprehensive NGS testing before starting any targeted agent.
This is called acquired resistance. The tumor has evolved a workaround — usually a new mutation, activation of a parallel pathway, or transformation to a different cancer type. The clinical response is: repeat biopsy (tissue or liquid) to identify the resistance mechanism, then switch to a next-generation drug that targets that specific resistance alteration. For example, if EGFR T790M emerges after a first-generation EGFR inhibitor, switching to Osimertinib (a third-generation EGFR TKI that covers T790M) is the standard next step.
When the matching mutation is present — yes, usually dramatically better. Targeted drugs typically have higher response rates (often 60-80% vs. 20-30% for chemo in molecularly selected patients), fewer severe side effects (they spare normal cells without the mutation), and are taken orally at home rather than via IV infusion. But if the mutation is absent, targeted therapy has zero efficacy — and chemotherapy may be the appropriate choice. This is why testing is non-negotiable.
This varies dramatically by drug and cancer type. First-generation EGFR inhibitors (Erlotinib, Gefitinib) typically work for 9-14 months before resistance emerges. Third-generation Osimertinib extends this to 18-24 months. Next-generation TKIs and combination strategies are pushing this further. Some targeted drugs (like Imatinib for CML) can control disease for decades. The key is that resistance, when it occurs, is not a dead end — it's a signal to re-biopsy and find the next targeted option.
Yes — and increasingly so. Many targeted drugs are available in China at 40-70% lower cost than US list prices, due to government-negotiated national reimbursement and domestic biosimilar competition. Domestic Chinese TKIs (e.g., Aumolertinib for EGFR, Ensartinib for ALK) have shown non-inferior efficacy to their Western counterparts in head-to-head trials. The approval lag between FDA and NMPA has also shrunk to less than 4 years for many oncology drugs, and some drugs now launch first in China.
A single-gene test checks for mutations in one gene only — for example, EGFR alone. If negative, you learn nothing about ALK, ROS1, BRAF, KRAS, HER2, MET, RET, NTRK, or any of the other actionable targets. A comprehensive NGS panel tests hundreds of genes simultaneously, including point mutations, fusions, and copy number changes — giving you the full picture in one test. If your oncologist only ordered a single-gene test, ask whether a comprehensive NGS panel (tissue or liquid) would be more informative for your specific cancer type.
Not Sure Which Targeted Drug Matches Your Mutation?
Submit your pathology report or NGS results. Our oncology team will cross-reference your molecular profile against the latest FDA, NMPA, and clinical trial landscape — and provide a personalized, evidence-based drug matching report within 48 hours.